LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling

Key Takeaways LLY shares fell 3.8% reportedly as FDA delays decision on oral obesity drug orforglipron.With oral Wegovy already approved, the delay gives NVO extra time to gain share in the obesity pill market.Orforglipron is also in late-stage studies for sleep apnea, osteoarthritis pain and hypertension.Eli Lilly and Company’s (LLY) stock declined 3.8% on Thursday after the FDA reportedly delayed its decision on LLY’s much-awaited oral GLP-1 drug called orforglipron. Reportedly, the FDA delayed its decisi ...